Latest news

06 Aug 2020
Idorsia Japan confirms daridorexant dose response in Japanese patients with insomnia – preparation for a local registration program advancing
23 Jul 2020
Idorsia announces financial results for the first half 2020
16 Jul 2020
Idorsia establishes US commercial operations and leadership team
06 Jul 2020
Idorsia announces positive results in the second Phase 3 study of daridorexant
20 May 2020
Idorsia successfully completes the offering of new shares thereby securing funding for the company’s growth plan
19 May 2020
Idorsia launches an offering of new shares to fund the company’s growth plan
13 May 2020
Idorsia holds its third Annual General Meeting of Shareholders
12 May 2020
Neurocrine Biosciences exercises option to license Idorsia's novel treatment for rare pediatric epilepsy
23 Apr 2020
Idorsia announces financial results for the first quarter 2020
20 Apr 2020
Idorsia announces positive results in the first Phase 3 study of daridorexant with improved overall sleep and daytime performance of patients with insomnia
02 Apr 2020
Idorsia issues Notice of the 2020 Annual General Meeting of Shareholders
19 Mar 2020
Janssen announces submission of New Drug Application to the U.S. FDA for ponesimod for treatment of adults with relapsing multiple sclerosis
04 Mar 2020
Janssen submits European Marketing Authorization Application for ponesimod for treatment of adults with relapsing multiple sclerosis
06 Feb 2020
Idorsia announces financial results for 2019 – clinical programs advanced markedly – approaching first key results
10 Jan 2020
Neurocrine Biosciences and Idorsia amend option agreement to license novel treatment for rare pediatric epilepsy
05 Dec 2019
Idorsia and Mochida enter into a license agreement for the supply, co-development and co-marketing of daridorexant in Japan
19 Nov 2019
Idorsia enters into a collaboration with Antares for the development of a novel self-administered drug-device product for selatogrel
11 Nov 2019
Encouraging Phase 2 data on cenerimod – Idorsia's S1P1 receptor modulator currently investigated for SLE – presented at ACR 2019
22 Oct 2019
Idorsia announces financial results for the first nine months of 2019
02 Oct 2019
Data on cenerimod – Idorsia's S1P1 receptor modulator – will be presented at the ACR / ARP Annual Meeting 2019